Unexplained fever in neonates may be associated with hepatitis B vaccine

Nehama Linder, Meirav Raz, Lea Sirota, Brian Reichman, Dan Lubin, Jacob Kuint, Avner Herman Cohen, Asher Barzilai

Abstract

Aim—To investigate whether hepatitis B vaccination has increased the number of cases of unexplained neonatal fever.

Method—The files of all infants born from 1 January 1991 to 31 December 1992, in whom a diagnosis of “injected antibiotic” or “disease of temperature regulation” was recorded, were reviewed. Those who had unexplained fever of 38°C or higher during the first three days of life were divided into two groups: infants who did not receive the hepatitis B vaccine (1991) and infants who did (1992).

Results—In 1992 the incidence of unexplained fever in hepatitis B vaccinated neonates was significantly higher than in the 1991 group of pre-vaccination neonates (35 out of 5819 (0.6%) vs 14 out of 5010 neonates (0.28%) respectively, p=0.013).

Conclusions—The increase in the number of cases of unexplained neonatal fever seems to be associated with the introduction of routine hepatitis B vaccination on the first day of life. The possibility that an excess number of neonates will undergo unnecessary procedures and treatment to diagnose unexplained fever justifies planning a controlled study to determine whether these preliminary findings point to a significant problem.

Arch Dis Child Fetal Neonatal Ed 1999;81:F206–F207

Keywords: hepatitis B vaccine; fever

Adverse events have been reported in 1.0 to 7.3% of infants who received hepatitis vaccine, the most common in neonates being fever (37.5–39°C) with an incidence of 1.0 to 3.7%.

Routine administration of hepatitis B vaccine to all neonates (0.6%) was significantly higher than in the 1991 group of pre-vaccination neonates (0.28%) respectively, p=0.013.

Table 1 Comparison of infants with neonatal fever before (1991) and after (1992) introduction of routine hepatitis B immunisation

<table>
<thead>
<tr>
<th></th>
<th>1991 group</th>
<th>1992 group</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total infants</td>
<td>5010</td>
<td>5819</td>
<td></td>
</tr>
<tr>
<td>Neonatal fever above 37.5°C</td>
<td>27</td>
<td>68</td>
<td>0.001</td>
</tr>
<tr>
<td>Neonatal fever above 38.0°C</td>
<td>27</td>
<td>50</td>
<td>0.05</td>
</tr>
<tr>
<td>Explained neonatal fever</td>
<td>13</td>
<td>15</td>
<td>NS</td>
</tr>
<tr>
<td>Unexplained neonatal fever</td>
<td>14</td>
<td>35</td>
<td>0.013</td>
</tr>
</tbody>
</table>

Discussion

Hepatitis B vaccine is the first vaccine to be universally recommended for neonates. The rate of febrile reaction to it reportedly ranges.
Unexplained fever in neonates may be associated with hepatitis B vaccine

from 0 to 7.3 hours.1 2 A lower rate of adverse events was reported in infants and children than in adults.1 In neonates the most common subsequent event was fever (37.5–39.0°C) and was the most common serious sign reported by the Vaccine Adverse Event Reporting System (VAERS).2 Their median reported time from vaccination to onset of fever was 1 day and mean maximum temperature was 38.9°C.

We reviewed the charts of infants with the diagnosis of temperature regulation disease, and of those who received intravenous antibiotics, to identify all infants with neonatal fever. The percentage of infants with unexplained fever during the first three days of life was significantly higher in 1992 (0.6%) than in 1991 (0.28%) when it was not given. The 0.32% difference is compatible with the 0 to 7.3% reported rate of febrile reaction to the vaccine.1 2 4–9 Notably, had we included infants with enteroviral illnesses in 1992, the monthly distribution of cases of unexplained neonatal fever was stable, except for November 1992, when eight cases were noted. No other changes in our nursery staff or routine policies were introduced during 1992.

In the report by VAERS 24 neonates had severe neonatal events after hepatitis B vaccination; fever was the most common serious neonatal event and was reported in 13 (54%) neonates. The 13 neonates with fever reported by VAERS were admitted for a median of three days and 10 underwent evaluation for sepsis.2 In our study, all 35 neonates underwent a full sepsis evaluation, intravenous antibiotic treatment, and prolonged hospital stay.

Although Israel has a low incidence of hepatitis B carriers among the general Jewish Israeli population 0.5–0.6%,2 11 the Ministry of Health decided to provide active immunization for every neonate on the first day of life, mainly because of the large scale immigration from countries in which the virus is hyperendemic. It was expected that since the rate of transmission of anti-hepatitis B antibodies from Israeli mothers to offspring is only 23%, there would be a good antibody response to an early first immunisation.10 11

In conclusion, we found that an increased incidence of unexplained neonatal fever, which resulted in evaluation for sepsis, administration of intravenous antibiotics, and prolonged hospital stay, may be associated with vaccination against hepatitis B on the first day of life. Although our data are significant, our numbers are small, therefore a larger controlled trial is justified to determine if the benefit conferred by universal vaccination of neonates against hepatitis B is outweighed by the risks and costs of unnecessary diagnostic procedures and treatments.